BR112014032987A2 - método de tratamento ou profilaxia de um distúrbio neurológico - Google Patents

método de tratamento ou profilaxia de um distúrbio neurológico

Info

Publication number
BR112014032987A2
BR112014032987A2 BR112014032987A BR112014032987A BR112014032987A2 BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2 BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
neurological disorder
œmethod
ago
Prior art date
Application number
BR112014032987A
Other languages
English (en)
Portuguese (pt)
Inventor
Krull David
Bullman Jonathan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112014032987A2 publication Critical patent/BR112014032987A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014032987A 2012-07-05 2013-07-03 método de tratamento ou profilaxia de um distúrbio neurológico BR112014032987A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668134P 2012-07-05 2012-07-05
PCT/EP2013/064063 WO2014006105A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
BR112014032987A2 true BR112014032987A2 (pt) 2017-06-27

Family

ID=48741180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032987A BR112014032987A2 (pt) 2012-07-05 2013-07-03 método de tratamento ou profilaxia de um distúrbio neurológico

Country Status (10)

Country Link
EP (1) EP2870177A1 (enExample)
JP (1) JP2015521992A (enExample)
KR (1) KR20150036398A (enExample)
CN (1) CN104395343A (enExample)
AU (1) AU2013285493A1 (enExample)
BR (1) BR112014032987A2 (enExample)
CA (1) CA2876284A1 (enExample)
IN (1) IN2014KN02952A (enExample)
RU (1) RU2014150265A (enExample)
WO (1) WO2014006105A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279751B1 (ko) * 2019-06-28 2021-07-21 경북대학교 산학협력단 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법
KR102409771B1 (ko) * 2020-06-17 2022-06-16 경북대학교 산학협력단 Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10336350B4 (de) 2003-08-08 2007-10-31 Westfalia Separator Ag Vollmantel-Schneckenzentrifuge, mit Schälscheibe
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
PL2207808T3 (pl) 2007-11-02 2013-11-29 Novartis Ag Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne
CA2730473A1 (en) 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment

Also Published As

Publication number Publication date
IN2014KN02952A (enExample) 2015-05-08
AU2013285493A1 (en) 2015-01-22
WO2014006105A1 (en) 2014-01-09
CN104395343A (zh) 2015-03-04
CA2876284A1 (en) 2014-01-09
EP2870177A1 (en) 2015-05-13
KR20150036398A (ko) 2015-04-07
JP2015521992A (ja) 2015-08-03
RU2014150265A (ru) 2016-08-27

Similar Documents

Publication Publication Date Title
MX394273B (es) Lipido que comprende acido docosapentaenoico.
SG10201903962PA (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112015024674A2 (pt) método para aumentar a capacidade de sobrevivência de um ou mais microrganismos benéficos e para revestir uma semente, e, composição
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
NZ715815A (en) High-stability t-cell receptor and preparation method and application thereof
BR112015028605A2 (pt) método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
TN2016000245A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors.
BR112013000768A2 (pt) asparaginase de basidiomicetos
MX2014010959A (es) Preparaciones de ester de acido fosforico con higroscopia reducida.
MX2015010077A (es) Terapia de combinacion para el tratamiento de neumonia nosocomial.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
BR112015031541A2 (pt) métodos para o impedimento da agregação de componentes virais
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
HK1223632A1 (zh) 靶向的酶化合物及其用途
UY32075A (es) Estabilización de preparaciones acuosas de minerales mediante reuterina
MX2015006616A (es) Doble direccion.
BR112014032987A2 (pt) método de tratamento ou profilaxia de um distúrbio neurológico
EA201491581A1 (ru) Везикулярные композиции
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
MX338405B (es) Formulaciones de 2-iminobiotina y sus usos.
CL2015002069A1 (es) Métodos para el uso de compuestos de fenoxipropilamina para tratar la depresión.
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)